CTLA4 and hepatocellular carcinoma: According to a previous investigation, the anti-CTLA4 and anti-PD-1 treatment reactivated the antitumor immune response in the TME of HCC (48), and the expression of immune checkpoint genes was associated with the response to ICI (8).